Monteplase

Monteplase is a fibrinolytic agent used in the treatment of acute myocardial infarction, more commonly known as a heart attack. It is a type of thrombolytic therapy, which is a treatment that dissolves blood clots. Monteplase is a recombinant DNA product, meaning it is produced through genetic engineering.

Mechanism of Action[edit | edit source]

Monteplase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the main component of blood clots. This process helps to restore blood flow in the blocked arteries, reducing the damage to the heart muscle.

Usage[edit | edit source]

Monteplase is administered intravenously, usually in a hospital setting, under the supervision of a healthcare professional. The dosage is determined by the patient's body weight and the severity of the condition.

Side Effects[edit | edit source]

Like all medications, Monteplase can cause side effects. The most common side effects include bleeding, allergic reactions, and arrhythmias. In rare cases, it can cause severe bleeding, including intracranial hemorrhage.

Contraindications[edit | edit source]

Monteplase is contraindicated in patients with active internal bleeding, history of stroke, or recent surgery. It should be used with caution in patients with high blood pressure, liver disease, or kidney disease.